HONG KONG – China has launched a two-invoice system for drug procurement as part of a change that underscores an ongoing reshuffle of the health care industry in the country. By limiting the number of invoices allowed in the drug distribution chain, the system aims to eliminate middlemen, avoid unnecessary invoicing that may facilitate corruption and increase transparency in drug pricing.